Context Therapeutics (CNTX)
NASDAQ:CNTX
Want to see CNTX full AI Analyst Report?
Top Page
Context Therapeutics
(NASDAQ:CNTX)
Select Model
Select Model
Rating:48Neutral
Price Target:
$2.50
▲(2.88% Upside)
Action:ReiteratedDate:05/02/26
The score is held down primarily by weak financial performance (no revenue, widening losses, and a history of cash burn despite low debt) and only modest technical momentum. Corporate developments provide some offset—especially FDA Fast Track for CTIM-76 and improved governance—but valuation support is limited given negative earnings and no dividend yield data.
Positive Factors
Regulatory Acceleration (Fast Track)
Fast Track status is a durable regulatory advantage: it can streamline interactions with FDA, enable rolling submissions, and often accelerate development timelines for high unmet-need oncology indications. Over 2–6 months this reduces regulatory risk and can de-risk the program versus competitors.
Negative Factors
Pre-revenue with Widening Losses
A sustained pre-revenue profile with materially widening net losses means the company must raise capital or secure partnerships to fund operations. Over a multi-month horizon this raises dilution and execution risk if clinical progress stalls and there is no near-term pathway to commercial revenue.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory Acceleration (Fast Track)
Fast Track status is a durable regulatory advantage: it can streamline interactions with FDA, enable rolling submissions, and often accelerate development timelines for high unmet-need oncology indications. Over 2–6 months this reduces regulatory risk and can de-risk the program versus competitors.
Read all positive factors
Context Therapeutics (CNTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$214.08M
Dividend YieldN/A
Average Volume (3M)830.13K
Price to Earnings (P/E)―
Beta (1Y)0.48
Revenue GrowthN/A
EPS Growth-24.56%
CountryUS
Employees12
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.38
Shares Outstanding91,879,170
10 Day Avg. Volume775,845
30 Day Avg. Volume830,128
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.31
Price to Sales (P/S)0.00
P/FCF Ratio-5.30
Enterprise Value/Market Cap0.77
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.52K
Enterprise Value/Ebitda-4.24
Forecast
1Y Price Target
$5.83Price Target Upside140.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.44
Revenue Forecast (FY)N/A
Context Therapeutics Business Overview & Revenue Model
Company Description
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antago...
How the Company Makes Money
null...
Context Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -124.66K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -39.70M | -29.91M | -25.06M | -14.87M | -10.39M |
| Net Income | -36.12M | -26.73M | -23.96M | -14.84M | -10.46M |
Balance Sheet | |||||
| Total Assets | 68.49M | 98.13M | 16.06M | 37.97M | 51.31M |
| Cash, Cash Equivalents and Short-Term Investments | 66.00M | 94.43M | 14.45M | 35.50M | 49.64M |
| Total Debt | 112.06K | 219.38K | 0.00 | 55.08K | 0.00 |
| Total Liabilities | 8.02M | 2.86M | 4.19M | 3.21M | 3.03M |
| Stockholders Equity | 60.47M | 95.27M | 11.87M | 34.76M | 48.27M |
Cash Flow | |||||
| Free Cash Flow | -26.42M | -29.31M | -21.05M | -14.09M | -9.05M |
| Operating Cash Flow | -26.39M | -14.56M | -21.05M | -13.55M | -8.80M |
| Investing Cash Flow | -2.03M | -14.76M | 0.00 | -536.84K | -250.00K |
| Financing Cash Flow | -15.27K | 109.29M | 0.00 | -102.07K | 58.39M |
Context Therapeutics Technical Analysis
Neutral
2.43
Price Trends
2.61
Negative
2.04
Positive
1.50
Positive
Market Momentum
-0.07
Positive
44.16
Neutral
21.55
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CNTX, the sentiment is Neutral. The current price of 2.43 is below the 20-day moving average (MA) of 2.63, below the 50-day MA of 2.61, and above the 200-day MA of 1.50, indicating a neutral trend. The MACD of -0.07 indicates Positive momentum. The RSI at 44.16 is Neutral, neither overbought nor oversold. The STOCH value of 21.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CNTX.
Context Therapeutics Risk Analysis
Context Therapeutics disclosed 56 risk factors in its most recent earnings report. Context Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Context Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $169.64M | -4.32 | -48.20% | ― | 7336.90% | 49.64% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $194.75M | -1.80 | -11.99% | ― | -100.00% | -1124.16% | |
48 Neutral | $214.08M | -7.18 | -59.95% | ― | ― | -24.56% | |
44 Neutral | $21.19M | -1.06 | 7743.57% | ― | ― | -25.06% | |
42 Neutral | $20.39M | -5.19 | -74.58% | ― | ― | 33.15% |
* Healthcare Sector Average
CNTX
Context Therapeutics
2.33
1.55
198.34%
WHWK
Whitehawk Therapeutics
3.94
2.24
131.76%
QNCX
Quince Therapeutics
1.30
-8.90
-87.25%
ADAG
Adagene
3.58
1.98
123.75%
ANEB
Anebulo Pharmaceuticals
0.50
-0.54
-51.92%
Context Therapeutics Corporate Events
Business Operations and StrategyLegal ProceedingsShareholder Meetings
Context Therapeutics settles governance lawsuit with mootness fee
Negative
May 1, 2026
On March 11, 2026, the Delaware Court of Chancery approved a consent judgment in a stockholder class action against Context Therapeutics, determining that charter provisions establishing three-year director terms and removal of directors only for ...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Context Therapeutics Gains FDA Fast Track for CTIM-76
Positive
Apr 2, 2026
On April 2, 2026, Context Therapeutics announced that the U.S. Food and Drug Administration granted Fast Track designation to CTIM-76, its investigational Claudin 6 x CD3 T cell engaging bispecific antibody, for patients with platinum-resistant ov...
Business Operations and Strategy
Context Therapeutics Highlights Evolving T Cell Engager Pipeline
Positive
Mar 23, 2026
On March 23, 2026, Context Therapeutics Inc. updated its corporate presentation for investor and analyst meetings, detailing a strategy to build a leading pipeline of T cell engager bispecific antibodies for solid tumors. The deck emphasizes three...
Business Operations and StrategyExecutive/Board ChangesLegal ProceedingsShareholder Meetings
Context Therapeutics Adopts Shareholder-Friendly Board Governance Changes
Positive
Mar 13, 2026
On March 11, 2026, the Delaware Court of Chancery approved a stipulated judgment in a stockholder class action against Context Therapeutics that invalidated provisions of its charter establishing three-year director terms and removal only for caus...
Business Operations and StrategyLegal ProceedingsShareholder Meetings
Context Therapeutics Reaches Governance Settlement, Plans Annual Elections
Neutral
Feb 27, 2026
On February 24, 2026, Context Therapeutics and the plaintiff in a February 4, 2026 stockholder class action filed a stipulated judgment in the Delaware Court of Chancery seeking to invalidate charter provisions that mandated three-year director te...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.